The therapeutic effects of WSY-0702 on benign prostatic hyperplasia in RWPE- 1

• 발행기관: 셀메드 세포교정의약학회
• 저자명: Hyun-A Oh Eun Bi Kwon Yun Gyeong Hwang Soon Eung Park Ji Ye Mok Sung Yeoun Hwang
• 간행물 정보: 『셀메드』Volume 7 Issue 2, 1~7쪽, 전체 7쪽
• 주제분류: 의약학 > 의학일반
• 파일형태: PDF
• 발행일자: 2017.05.31

영문 초록

Benign prostatic hyperplasia (BPH) is one of the major diseases of the urinary system in older men. WSY-0702 is the extracted from the traditional medicinal plant; Seoritae, and it has effects of anti-obesity, chronic cervical pain, and anti-oxidant. The present study aimed to investigate the therapeutic potential of WSY-0702 in the prevention and treatment of BPH. Several parameters including inflammatory mediators, hormones, and oxidative stress (OS) have been considered to play a role in the development of BPH. Prostate tissue damage and OS may lead to compensatory cellular proliferation with resulting hyperplastic growth. An in vitro study showed that proliferation inhibited the human prostate epithelial cell line RWPE-1 in a dose-dependent manner. In cell line, the cell cycle at the G2/M and G0/G1 phase and downregulated the expression of CyclineB1 (CCNB1) and CyclineD1 (CCND1). In addition, we measured the H2O2-induced OS damage using RWPE-1 cells. We examined the relative expression of protein involved in the regulation of prostate apoptosis: transforming growth factor (TGF)-β, a negative growth factor able to induced prostate apoptosis under physiological conditions. These results suggest that WSY-0702 that can inhibit the growth of prostate epithelial cell by a mechanism that may involve arresting the cell cycle and downregulating CCNB1 and CCND1 expression. In addition, WSY-0702 exposure resulted in significant protective effects in H2O2-stressed PWPE-1 cells by reduction in TGF-β levels.

키워드

WSY-0702 benign prostatic hyperplasia anti-oxidant human prostatic epithelial cell line cell cycle